Skip to content

Evaluation of bone marrow hypoxia with 18F-FAZA PET in patients with relapsing multiple myeloma; a pilot study

Evaluation of bone marrow hypoxia with 18F-FAZA PET in patients with relapsing multiple myeloma; a pilot study - F-FAZA MM

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON35390
Enrollment
10
Registered
2011-11-23
Start date
2011-09-01
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma and Kahler's disease

Interventions

None listed

Sponsors

Hematologie
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patient with a positive FDG-PET scan. Patients with relapsing multiple myeloma according to international defined guidelines.;Relapse after having achieved complete remission. 1. Reappearance of paraprotein 2. More than 5% plasma cells in bone marrow. 3. New lytic lesions or progression of old lesions. 4. New hypercalceamia.;Relapse after having achieved partial remission 1. Increases of paraprotein with more than 25% 2. Increase of urine paraprotein with more than 25% 3. Increase of plasma cells in bone marrow with 10% 4. New lytic lesions or progression of old lesions 5. New hypercalceamia

Exclusion criteria

Exclusion criteria: - Radiotherapy in the last 3 months. - Ineligible to lay supine during the PET scan. - Age =250 µM.

Design outcomes

Primary

MeasureTime frame
Feasibility of 18F-FAZA scans in patients with relapsing multiple myeloma. In addition bone marrow staining to demonstrate whether hypoxia related proteins are upregulated by plasma cells or surrounding cells including HIF 1a , HIF2a , GLUT-1 and -3 and VEGF.

Secondary

MeasureTime frame
not applicable.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)